Man Group’s Nurix Therapeutics NRIX Stock Holding History

Man Group’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.08M	Buy	+85,583	New	+$1.46M	﹤0.01%	1550
2025 Q3	–	Sell	-28,303	Closed	-$322K	–	2386
2025 Q2	$322K	Buy	+28,303	New	+$306K	﹤0.01%	1947
2024 Q3	–	Sell	-11,225	Closed	-$234K	–	2126
2024 Q2	$234K	Buy	+11,225	New	+$175K	﹤0.01%	1853
2024 Q1	–	Sell	-19,248	Closed	-$199K	–	2227
2023 Q4	$199K	Buy	+19,248	New	+$132K	﹤0.01%	1921
2023 Q3	–	Hold	0	–	–	–	1772

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Man Group's NRIX Position: Q2 2026 in Review

Man Group opened a new position in Nurix Therapeutics (NRIX) in Q2 2026: 85,583 shares worth $2.08M. The stake represents ﹤0.01% of the portfolio and ranks #1550 among its holdings. This is a return to the name: Man Group previously reported a position in NRIX as recently as Q2 2025.

Man Group first reported a position in NRIX in Q4 2023 and has held it in 4 quarters since. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

Man Group held 85,583 shares of Nurix Therapeutics worth $2.08M as of Q2 2026.
Nurix Therapeutics was a new Man Group position in Q2 2026.
Nurix Therapeutics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1550 holding.
Man Group first reported a position in Nurix Therapeutics in Q4 2023 and has held it in 4 quarters since.
212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.